ArticlebioRxiv : the preprint server for biology2026
Structural basis of phosphatidylserine enhancement of Gas6 ligand-induced Axl activation.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
TAMs (Tyro3, Axl, and MerTK) are receptor tyrosine kinases with primary roles in apoptotic clearance and immune suppression. In apoptosis, bridging complexes form between TAM receptors on phagocytic cells and TAM ligands bound to phosphatidylserine exposed on the surface of dying cells, but how these complexes form or why lipid is required for receptor activation is poorly understood. We present the first structures of a complete TAM receptor (Axl) and ligand (Gas6) 2:2 bridging complex with and without lipid, which suggest that the lipid functions to stabilize and promote active complexes. We also observe a stable 1:1 complex, presumed to be inactive, and provide evidence that these complexes are conversely able to form higher-order oligomers. We propose a mechanism for how lipids promote TAM receptor activation, providing a structural and biochemical basis for developing therapies that selectively target the lipid-dependent, immunosuppressive arm of TAM signaling exploited by tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.